5-Alpha Reductase and Anabolic Effects of Testosterone

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00475501
First received: April 16, 2007
Last updated: October 8, 2013
Last verified: October 2013
  Purpose

The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.


Condition Intervention Phase
Male Hypogonadism
Muscle Atrophy
Prostate Enlargement
Sarcopenia
Drug: Testosterone Enanthate
Behavioral: Collection of 3-day food logs with counseling of subjects
Drug: Finasteride
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 5-Alpha Reductase and Anabolic Effects of Testosterone

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • 1-RM strength testing for 5 exercises will be performed using dynamic resistance exercise machines. Testing will be performed before treatment (baseline), at 3, 6, 9 and 12 months after treatment and at 3 months after completion of treatment. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Grip strength in the dominant arm will be measured by using a Jamar dynamometer. Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Functional reach is measured as the furthest a subject can reach forward without taking a step. Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Dual x-ray absorptiometry (DXA): We will assess bone mineral density (BMD) and body composition using a fan-bean densitometer (Lunar Prodigy, GE Medical Systems). [ Time Frame: baseline, 12 months ] [ Designated as safety issue: No ]
  • Geriatric Depression Scale (GDS): This 30-item, yes/no questionnaire will be administered at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Rey Osterrieth Complex Figure (ROCF) test is a widely used standardized neuropsychological test for assessing visuospatial constructional functions, visuographic memory, and some aspects of planning. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Trail-Making Test, Parts A&B (Trails A&B): is a standardized test of cognitive function which specifically assesses working memory, visual processing, visual spatial skills, selective and divided attention, and psychomotor coordination. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Benton Judgment of Line Orientation Test is a standardized test with 30 items that is specific for visual spatial cognition. Tests will be administered at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: Yes ]
  • Blood analysis will be performed as follows: CBC (complete blood count), CMP (complete metabolic profile), Hgb A1C, LH, lipids, total testosterone, bioavailable testosterone and IGF-I. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]
  • Dietary protein intake will be assessed using a 3-day food log and subjects will be counseled to increase protein intake if needed using the guide "Healthy Ways to Eat More Protein". [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: Yes ]
  • Transrectal ultrasound sizing of prostate will be performed using the B&K Diagnostic System 3535, with 7MHz transrectal probe at baseline and after 6 and 12 months of treatment. [ Time Frame: baseline, 6 month, 12 months ] [ Designated as safety issue: No ]
  • Life Satisfaction: is a written test of psychological well-being that will be performed at baseline, after 3, 6, 9 and 12 months of treatment and at follow-up. [ Time Frame: baseline, 3 months, 6 months, 9 months, 12 months, 6 month followup ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: January 2007
Estimated Study Completion Date: March 2014
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
testosterone enanthate
Drug: Testosterone Enanthate
125 mg, i.m. injection, once/week, for 52 weeks
Behavioral: Collection of 3-day food logs with counseling of subjects
subject weighs food portions and completes food log, once/3 months, for 18 months (including 6-month follow-up. Counseling will be healthy ways to increase protein intake, if needed.
Experimental: Arm 2
finasteride
Drug: Finasteride
5 mg, oral, once/day, for 52 weeks
Behavioral: Collection of 3-day food logs with counseling of subjects
subject weighs food portions and completes food log, once/3 months, for 18 months (including 6-month follow-up. Counseling will be healthy ways to increase protein intake, if needed.
Experimental: Arm 3
testosterone enanthate + finasteride
Drug: Testosterone Enanthate
125 mg, i.m. injection, once/week, for 52 weeks
Drug: Finasteride
5 mg, oral, once/day, for 52 weeks
Behavioral: Collection of 3-day food logs with counseling of subjects
subject weighs food portions and completes food log, once/3 months, for 18 months (including 6-month follow-up. Counseling will be healthy ways to increase protein intake, if needed.
Placebo Comparator: Arm 4
placebo
Behavioral: Collection of 3-day food logs with counseling of subjects
subject weighs food portions and completes food log, once/3 months, for 18 months (including 6-month follow-up. Counseling will be healthy ways to increase protein intake, if needed.

Detailed Description:

Approximately 40% of older male veterans have a low serum testosterone concentration. The latter is associated with diminished muscle strength and bone mineral density, depressed mood, low pain tolerance, frailty, and increased mortality. Replacement doses of testosterone have been administered to hypogonadal men for the purpose of reversing deficits in muscle and bone. Although testosterone is clearly important for maintaining muscle and bone in men, there are problems associated with T replacement. First, testosterone causes a number of undesired effects, including fluid retention, gynecomastia, worsening of sleep apnea, polycythemia, prostate enlargement and acceleration of early-stage prostate cancer. The anabolic effects obtained to date from testosterone replacement have been relatively modest, especially in older men. Our hypothesis is that combined treatment with a higher-than-replacement dose of testosterone and a 5- reductase inhibitor will produce substantial anabolic effects, while preventing testosterone-induced prostate enlargement and possibly other adverse effects.

We plan to investigate the efficacy and safety of combined treatment with testosterone and finasteride in older hypogonadal male veterans by conducting a 12-month randomized, placebo-controlled trial. We will administer a higher-than-replacement dose of testosterone plus the 5- reductase inhibitor finasteride to a group of hypogonadal, but otherwise healthy older men. We will determine whether this treatment is a safe and effective means to increase muscle mass and strength. Men aged 60 to 80, with circulating total testosterone 300 ng/dL or bioavailable testosterone 70 ng/dL, will be treated with 125 mg testosterone enanthate/week 5 mg finasteride/day for 1 year. We will assess the effects on body composition, 1-RM strength, grip strength, functional reach, bone mineral density, mood, cognition, hematopoiesis and prostate volume. We have chosen a moderately high dose of testosterone that may cause some adverse effects. We predict that finasteride will not block the anabolic effects of testosterone, but will block any prostate enlargement or symptoms and possibly other adverse effects as well.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age > 60 years males
  • Primary care at the Malcolm Randall VA Medical Center in Gainesville, FL.
  • Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusion criteria will be randomized to receive either testosterone or placebo.

Exclusion Criteria:

  • Subjects with cognitive impairment will be identified by the Mini-Cog test and excluded. The Mini-Cog has high sensitivity and specificity for cognitive impairment, and is not affected by level of education.
  • We will also exclude subjects with receptive aphasia, or a contraindication to testosterone replacement (i.e., history of or active prostate or breast cancer, severe benign prostatic hyperplasia (AUA SI > 25), congestive heart failure (Class 3 or 4), sleep apnea syndrome, polycythemia (Hct > 55%), or PSA > 2.6 ng/mL) will be excluded.
  • Obese subjects (BMI > 35) will also be excluded.
  • Subjects currently receiving testosterone supplementation or subjects who have an allergy to testosterone will also be excluded.
  • Subjects previously receiving testosterone replacement therapy must be off such medication for at least four weeks.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00475501

Locations
United States, Florida
North Florida/South Georgia Veterans Health System
Gainesville, Florida, United States, 32608
Sponsors and Collaborators
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Stephen Borst, PhD North Florida/South Georgia Veterans Health System
  More Information

Publications:
Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00475501     History of Changes
Other Study ID Numbers: ENDA-014-05F, VA Merit
Study First Received: April 16, 2007
Last Updated: October 8, 2013
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
anabolic effects
finasteride
male hypogonadism
sarcopenia
testosterone

Additional relevant MeSH terms:
Hypertrophy
Hypogonadism
Muscular Atrophy
Eunuchism
Atrophy
Prostatic Hyperplasia
Sarcopenia
Pathological Conditions, Anatomical
Gonadal Disorders
Endocrine System Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Prostatic Diseases
Genital Diseases, Male
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
Anabolic Agents
Finasteride
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 17, 2014